The histone deacetylase inhibitor LBH589 inhibit undifferentiated pleomorphic sarcoma growth via downregulation of FOSL1

被引：0
|
作者：
Saitoh, Yoshinobu [1 ]
Setoguchi, Takao [1 ]
Nagano, Satoshi [1 ]
Taniguchi, Noboru [1 ]
机构：
[1] Kagoshima Univ, Dept Orthop Surg, Kagoshima, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3419
引用
收藏
页码：1416 / 1416
页数：1
相关论文
共 50 条
  • [1] The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1
    Saitoh, Yoshinobu
    Bureta, Costansia
    Sasaki, Hiromi
    Nagano, Satoshi
    Maeda, Shingo
    Furukawa, Tatsuhiko
    Taniguchi, Noboru
    Setoguchi, Takao
    MOLECULAR CARCINOGENESIS, 2019, 58 (02) : 234 - 246
  • [2] The histone deacetylace inhibitor, LBH589, inhibits the proliferation of the UPS cells via down regulation of FOSL1
    Saitoh, Yoshinobu
    Setoguchi, Takao
    Nakashima, Takayuki
    Nagano, Satoshi
    Komiya, Setsuro
    CANCER SCIENCE, 2018, 109 : 621 - 621
  • [3] Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
    Leslie A. Garrett
    Whitfield B. Growdon
    Bo R. Rueda
    Rosemary Foster
    Journal of Ovarian Research, 9
  • [4] Influence of the novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
    Garrett, L.
    Zhang, L.
    Guo, L.
    Therrien, V.
    Growdon, W.
    Foster, R.
    Rueda, B.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S71 - S71
  • [5] Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
    Garrett, Leslie A.
    Growdon, Whitfield B.
    Rueda, Bo R.
    Foster, Rosemary
    JOURNAL OF OVARIAN RESEARCH, 2016, 9
  • [6] The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
    Maiso, Patricia
    Carvajal-Vergara, Xonia
    Ocio, Enrique M.
    Lopez-Perez, Ricardo
    Mateo, Gema
    Gutierrez, Norma
    Atadja, Peter
    Pandiella, Atanasio
    San Miguel, Jesus F.
    CANCER RESEARCH, 2006, 66 (11) : 5781 - 5789
  • [7] Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo
    Catalano, Maria Graziella
    Pugliese, Mariateresa
    Gargantini, Eleonora
    Grange, Cristina
    Bussolati, Benedetta
    Asioli, Sofia
    Bosco, Ornella
    Poli, Roberta
    Compagnone, Alessandra
    Bandino, Andrea
    Mainini, Franco
    Fortunati, Nicoletta
    Boccuzzi, Giuseppe
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (03) : 694 - 704
  • [8] Histone deacetylase inhibitor, LBH589, synergizes with an immunotherapy treatment in an in vivo murine brain tumor model
    Lisiero, Dominique Naomi
    Soto, Horacio
    Fang, Shanna
    Ribas, Antoni
    Liau, Linda
    Prins, Robert
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [9] Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells
    Xiao, Weiwei
    Graham, Peter H.
    Hao, Jingli
    Chang, Lei
    Ni, Jie
    Power, Carl A.
    Dong, Qihan
    Kearsley, John H.
    Li, Yong
    PLOS ONE, 2013, 8 (08):
  • [10] The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
    Klein, Jan M.
    Henke, Alexander
    Sauer, Maike
    Bessler, Martina
    Reiners, Katrin S.
    Engert, Andreas
    Hansen, Hinrich P.
    von Strandmann, Elke Pogge
    PLOS ONE, 2013, 8 (11):
12345